RCKT (Rocket Pharmaceuticals) Payments of Debt: $-0.00 Mil (TTM As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
25 GF Score
Price $3.99
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Payments of Debt?

Rocket Pharmaceuticals RCKT +3.91% 25 Payments of Debt is $-0.00 Mil as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review.

Rocket Pharmaceuticals's Payments of Debt for the three months ended in Mar. 2026 was $-0.00 Mil.

Rocket Pharmaceuticals's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.00 Mil.

Rocket Pharmaceuticals Payments of Debt Related Terms

Rocket Pharmaceuticals Payments of Debt Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Payments of Debt Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
RCKT
25GF Score
Rocket Pharmaceuticals Inc RCKT
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $-0.00 Mil mean?
Rocket Pharmaceuticals (RCKT) has a Payments of Debt of $-0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' Payments of Debt too high?
Rocket Pharmaceuticals' current Payments of Debt is $-0.00 Mil. Overall, Rocket Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Payments of Debt compare to TENX and DMAC?
Rocket Pharmaceuticals' Payments of Debt of $-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current Payments of Debt is $-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Payments of Debt of $-0.00 Mil. The current Payments of Debt is $-0.00 Mil. Rocket Pharmaceuticals' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Payments of Debt is $-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
25GF Score

Get the complete analysis for RCKT

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.99
Price